A Danish Nationwide Clinical Trial on Targeted
Cancer Treatment Based on Genomic Profiling


Latest News

News from the ProTarget trial

The cohort including patients (pts.) with BRAF V600-mutated neuroendocrine carcinoma (NEC) for treatment with Cotellic (cobimetinib) and Zelboraf (vemurafenib) has completed the first stage of accrual. The cohort has been evaluated and since treatment benefit ...
Read More
March 8th, 2024, the Phase 1 Unit and Department of Genomic Medicine, Rigshospitalet, will co-host a symposium celebrating 10 years with the Copenhagen Prospective Personalized Oncology study. The symposium will be bridging genomic research and clinical oncolo...
Read More
About us
The ProTarget study - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on Genomic Profiling

The ProTarget study is a Danish investigator-initiated phase 2 clinical trial that aims to facilitate patient access to commercially available molecularly targeted anti-cancer drugs based on tumor genomic profiling.

The trial aims to investigate the safety and efficacy of these treatments, when they are used outside the labeled indication to treat patients with relevant actionable targets. By doing this, we aim to identify new predictive biomarkers for targeted treatments outside the labeled indication and provide new data and essential insights in molecular pathways involved in e.g., resistance to targeted therapies.

Read more